MarketCap
Facebook
X
Telegram
Altimmune Income Statement 2025-2009 | ALT
Brief overview of profit and loss at Altimmune
The comparison covers a five-year financial horizon. Revenue at Altimmune moved from 8.2 million dollars in 2020 to 41 thousand dollars in 2025. The total change was −99.5%, with a CAGR of approximately −65.3%. Sales followed a declining trajectory over the five years.
Over the period, EBITDA shifted from −54.5 million dollars to −94.4 million dollars, a change of −73.2%. The operating result outpaced sales and points to improving efficiency. EBITDA margin moved from −665.9% to −230187.8%. Cost pressure reduced operating profitability.
Comparing the endpoints shows a move from −49 million dollars to −88.1 million dollars. Profitability deteriorated further over the five years.
The five-year change in capitalization reached −32.6%: from 472 million dollars to 318 million dollars. The negative valuation trend points to increased investor caution.
Overall conclusion
The indicators point to a weaker financial profile. The main areas of concern are a softer top-line trend, pressure on operating profitability and limited operating profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Altimmune
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
318 M | 463 M | 473 M | 593 M | 333 M | 472 M | 23.2 M | 9.3 M | 23.4 M | 5.66 K | 3.31 M | 4.03 M | 443 K | 362 K | 189 K | - | - |
Shares |
88.1 M | 71 M | 53.2 M | 46.9 M | 41.3 M | 33.1 M | 13.1 M | 2.8 M | 427 K | 218 K | 213 K | 192 K | 169 K | 161 K | 158 K | 32.3 M | - |
Historical Prices |
3.61 | 6.52 | 8.89 | 12.6 | 8.07 | 14.3 | 1.72 | 3.19 | 54.3 | - | - | - | - | - | - | ||
Net Income |
-88.1 M | -95.1 M | -88.4 M | -84.7 M | -97.1 M | -49 M | -20.5 M | -39.2 M | -46.4 M | 194 M | -3.44 M | -9.96 M | -11.7 M | -4.92 M | -3.8 M | -34.8 M | - |
Revenue |
41 K | 20 K | 426 K | -68 K | 4.41 M | 8.19 M | 5.8 M | 10.3 M | 10.7 M | 5.23 M | 10.6 M | 10.2 M | 17.9 M | 25.2 M | 24.3 M | 21 M | - |
Gross Profit |
- | - | - | - | - | 8.18 K | - | - | - | - | 10.6 M | 10.2 M | 17.9 M | 25.2 M | 24.3 M | - | - |
Operating Income |
-94.5 M | -103 M | -95.9 M | -87.7 M | -96.9 M | -54.8 M | -21.5 M | -42.8 M | -52 M | -11.1 M | -3.4 M | -10.2 M | -10.8 M | -6.27 M | -11.7 M | -23.6 M | - |
Interest Expense |
-190 K | 48 K | 35 K | 8 K | 5 K | 9.42 K | 2.24 K | 297 K | 162 K | 38.5 K | 54.6 K | 210 K | 367 K | 325 K | 54.6 K | 5.94 M | - |
EBITDA |
-94.4 M | -103 M | -95.5 M | -87.9 M | -96.4 M | -54.5 M | -20.1 M | -17.6 M | -16 M | -11.1 M | -715 K | -10 M | -10.7 M | -5.96 M | -11.3 M | -22.5 M | - |
Operating Expenses |
94.5 M | 103 M | 96.4 M | 87.7 M | 101 M | 63 M | 26.3 M | 28.2 M | 26.9 M | 16.5 M | 11.5 M | 20.4 M | 28.8 M | 31.4 M | 36 M | 44.5 M | - |
General and Administrative Expenses |
28.1 M | 21 M | 18.1 M | 17.1 M | 15.4 M | 13.2 M | 8.5 M | 9.77 M | 8.46 M | 11.5 M | 6.22 M | 10.9 M | 13.3 M | 11.6 M | 14.3 M | 18 M | - |
All numbers in USD currency
Quarterly Income Statement Altimmune
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
124 M | 89.4 M | 81.5 M | 75.5 M | 72.4 M | 71.1 M | 70.9 M | 70.8 M | 70.7 M | 53.6 M | 50.7 M | 50.1 M | 49.2 M | 49.3 M | 47.5 M | 44 M | 41 M | 41.4 M | 41.4 M | 38.9 M | 37.1 M | 33.1 M | 17.9 M | 15.1 M | 15.3 M | 14.8 M | 13.1 M | 9.49 M | 9.08 M | 1.32 M | 956 K | 677 K | 608 K | 518 K | 12.2 M | 6.92 M | 6.92 M | 65 M | 64.7 M | 64.4 M | 64.4 M | 64.2 M | 63.7 M | 63.6 M | 63.6 M | 59 M | 54.7 M | 53 M | 52.3 M | 52.2 M | 49.7 M | 48.4 M | 48.4 M | 48.3 M | 48.3 M | 48.3 M | 48.2 M | 48.2 M | 46.6 M | 46.3 M |
Net Income |
-22.6 M | -19 M | -22.1 M | -19.6 M | - | -22.8 M | -24.6 M | -24.4 M | - | -20.7 M | -16.1 M | -20.1 M | - | -23.5 M | -20.1 M | -19.4 M | - | -33.5 M | -24.8 M | -14.9 M | - | -17.8 M | -16.8 M | -3.89 M | - | -10.9 M | -3.39 M | -2.1 M | - | -2.35 M | -9.14 M | -3.17 M | - | -29.9 M | -3.11 M | -4.58 M | 77.8 M | -4.8 M | -1.62 M | -1.23 M | -1.24 M | -1.32 M | -2.34 M | 1.46 M | -2.63 M | -4.63 M | -439 K | -2.26 M | -4.42 M | -3.95 M | -1.24 M | -2.11 M | -1.27 M | -214 K | -757 K | -2.68 M | 749 K | -33.5 K | -2.44 M | -2.08 M |
Revenue |
5 K | 5 K | 5 K | 5 K | - | 5 K | 5 K | 5 K | - | 362 K | 6 K | 21 K | - | 2 K | 8 K | 32 K | - | 158 K | 137 K | 838 K | - | 2.94 M | 722 K | 2.21 M | - | 644 K | 1.63 M | 2.96 M | - | 2.63 M | 2.42 M | 2.69 M | - | 4.59 M | 3.04 M | 300 K | - | 901 K | 746 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-24.2 M | -20.9 M | -22.9 M | -21.8 M | - | -24.8 M | -26.7 M | -26.8 M | - | -22.5 M | -18 M | -21.8 M | - | -24.8 M | -20.4 M | -19.5 M | - | -33.2 M | -24.9 M | -14.9 M | - | -18.3 M | -18.4 M | -7.31 M | - | -11.3 M | -3.55 M | -2.33 M | - | -4.06 M | -5.44 M | -5.99 M | - | -31 M | -4.01 M | -4.52 M | -5.51 M | -4.79 M | -1.6 M | -1.25 M | -940 K | -1.66 M | -1.96 M | 1.16 M | -2.62 M | -4 M | -1.17 M | -2.4 M | -5.07 M | -3.2 M | -1.48 M | -1.09 M | -1.43 M | -1.79 M | -1.46 M | -1.59 M | -1.08 M | -3.02 M | -3.08 M | -4.54 M |
Interest Expense |
-152 K | -86 K | -92 K | 15 K | - | 18 K | -76 K | -12 K | - | 14 K | 113 K | 2 K | - | 64 K | 65 K | 62 K | - | 33 K | 22 K | 12 K | - | 2.28 K | 3.31 K | 1.88 K | - | 756 | 748 | 740 | - | 167 K | 1.92 K | 870 | - | 2.34 K | 97.2 K | 60.6 K | - | 9.41 K | 9.62 K | 1.05 K | - | 9.89 K | 13.3 K | 25.3 K | - | 46.9 K | 56.6 K | 69.9 K | - | 89.8 K | 100 K | 99.8 K | - | 113 K | 111 K | 3.03 K | - | 9.93 K | 15.2 K | 15.4 K |
EBITDA |
-24.2 M | - | - | -21.8 M | - | - | - | -26.7 M | - | - | - | -22.1 M | - | -24.7 M | -20.2 M | -19.4 M | - | -32.8 M | -24.7 M | -14.8 M | - | -18.1 M | -18.3 M | -7.23 M | - | -11.1 M | -3.43 M | -2.27 M | - | -3.91 M | -5.36 M | -5.97 M | - | -30.9 M | -3.97 M | -4.5 M | -5.51 M | -4.76 M | -1.56 M | -1.22 M | -940 K | -1.62 M | -1.93 M | 1.2 M | -2.62 M | -3.96 M | -1.13 M | -2.36 M | -5.07 M | -3.15 M | -1.44 M | -1.04 M | -1.43 M | -1.72 M | -1.38 M | -1.5 M | -1.08 M | -2.91 M | -2.96 M | -4.42 M |
Operating Expenses |
24.2 M | 20.9 M | 22.9 M | 21.8 M | - | 24.8 M | 26.8 M | 26.8 M | - | 22.9 M | 18 M | 21.8 M | - | 24.8 M | 20.4 M | 19.5 M | - | 33.4 M | 25 M | 15.7 M | - | 21.3 M | 19.1 M | 9.52 M | - | 11.9 M | 5.18 M | 5.28 M | - | 6.69 M | 7.85 M | 8.69 M | - | 35.5 M | 7.05 M | 4.82 M | - | 5.69 M | 2.35 M | 2.26 M | - | 2.81 M | 3.11 M | 5.91 M | - | 4.96 M | 4.83 M | 6.14 M | - | 6.69 M | 5.78 M | 7.57 M | - | 8.49 M | 7.78 M | 7.74 M | - | 8.28 M | 9.51 M | 10.9 M |
General and Administrative Expenses |
8.05 M | 5.9 M | 5.69 M | 5.99 M | - | 4.97 M | 5.6 M | 5.31 M | - | 4.51 M | 4.76 M | 4.53 M | - | 4.49 M | 4.41 M | 4.43 M | - | 4.16 M | 3.66 M | 3.82 M | - | 4.22 M | 2.55 M | 2.33 M | - | 2.19 M | 2.23 M | 2.07 M | - | 1.96 M | 2.93 M | 2.45 M | - | 3.04 M | 1.79 M | 2.03 M | - | 3.29 M | 967 K | 1.19 M | - | 1.23 M | 1.82 M | 2.2 M | - | 3.19 M | 2.42 M | 2.68 M | - | 4.09 M | 2.33 M | 2.28 M | - | 3.28 M | 2.78 M | 2.95 M | - | 3.28 M | 3.41 M | 4.94 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Altimmune (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
